序号 |
标题 |
次数 |
作者 |
发布时间 |
86716 |
cas:1262403-90-6 七肽DOTA-VLASSAR |
96 |
zyl |
2024-11-21 |
86717 |
DOTA-DGln-DGln-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2 |
91 |
wyh |
2024-11-21 |
86718 |
DOTA-NOC ;619300-53-7 |
103 |
wyh |
2024-11-21 |
86719 |
DOTA-奥曲肽,DOTA-Octreotide |
153 |
zyl |
2024-11-21 |
86720 |
DOTA-PEG5-amine ;DOTA-PEG5-NH2 |
90 |
wyh |
2024-11-21 |
86721 |
DOTA修饰肽,1180007-00-4,二肽Z-GGRDOTA |
93 |
zyl |
2024-11-21 |
86722 |
DOTA-PEG5-amine ;DOTA-PEG5-NH2 |
92 |
wyh |
2024-11-21 |
86723 |
DOTA-RGD,DOTA-cRGDfK |
147 |
zyl |
2024-11-21 |
86724 |
DOTA-Lys-Cys-Acid 二肽DOTA-Lys-Cys |
114 |
wyh |
2024-11-21 |
86725 |
DOTA-Ala-Ala-COOH ;DOTA-丙氨酸-丙氨酸-羧酸 |
129 |
wyh |
2024-11-21 |
86726 |
cas:1293368-74-7,DOTA标记的多肽 |
140 |
zyl |
2024-11-21 |
86727 |
Azido-mono-amide-DOTA ;1227407-76-2 |
79 |
wyh |
2024-11-21 |
86728 |
Gd-DOTA-HCBP-1(多肽核磁共振成像(MRI)探针) |
115 |
zyl |
2024-11-21 |
86729 |
DOTA octreotide,大环配体奥曲肽 |
150 |
zyl |
2024-11-21 |
86730 |
DOTA-(D-Gln)3-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2,DOTA修饰多肽 |
86 |
zyl |
2024-11-21 |
86731 |
二聚体多肽 cas:250612-06-7 dota-glu[cyclo(arg-gly-asp-d-phe-lys)]2 |
131 |
zyl |
2024-11-21 |
86732 |
DBCO-SS-PEG-DOTA 二苯并环辛炔-聚乙二醇之四氮杂环十二烷 |
110 |
zyl |
2024-11-21 |
86733 |
(R)-C3-TUNAPHOS,cas:301847-89-2, R -( - )-1,13 -双(二苯基膦)-7,8 -二氢的6H -二苯H |
140 |
zcy |
2024-11-21 |
86734 |
Br-C3-methyl ester,cas:4897-84-1,4-溴丁酸甲酯 |
127 |
zcy |
2024-11-21 |
86735 |
DOTA-(COOt-Bu)3-C4-NH2,1402393-59-2,烷基链化合物或碳链化合物 |
111 |
zcy |
2024-11-21 |
86736 |
Gal-C4-Chol,cas:219850-70-1,糖基化胆固醇衍生物 |
154 |
zcy |
2024-11-21 |
86737 |
DOTAGA-DTyr(3I)-DPhe-DLys(Sub-Lys-urea-Glu) |
95 |
zyl |
2024-11-21 |
86738 |
Boc-C1-PEG2-C4-Cl,cas:1835705-53-7,烷基链化合物或碳链化合物 |
91 |
zcy |
2024-11-21 |
86739 |
AP-C6,cas:2234276-60-7, 烷基链化合物或碳链化合物 |
142 |
zcy |
2024-11-21 |
86740 |
cas:467456-19-5,6-(N-6-羟基己基)酰胺荧光素, 6-FAM-C6-OH |
219 |
zcy |
2024-11-21 |
86741 |
1262403-91-7 ;七肽DOTA-YLYEIAR |
135 |
wyh |
2024-11-21 |
86742 |
cas:1261350-60-0,NH2-PEG3-C6-Cl,烷基链化合物或碳链化合物 |
127 |
zcy |
2024-11-21 |
86743 |
...RGD,[18F]FB-c(RGDyK),N-4-[18F]Fluorobenzoyl-c(RGDyK... |
120 |
wyh |
2024-11-21 |
86744 |
C6 Urea Ceramide,cas:486991-52-0,D-赤型-N-[2-(1,3-二羟基-4E-十八碳烯)]-N'-己烷-脲-鞘氨醇 |
88 |
zcy |
2024-11-21 |
86745 |
1262403-90-6 ;七肽DOTA-VLASSAR |
125 |
wyh |
2024-11-21 |
86746 |
SPDP-C6-NHS ester,cas:158913-22-5,琥珀酰亚胺基-6-[3-(2-吡啶基二硫基)丙酰胺基]己酸 |
181 |
zcy |
2024-11-21 |
86747 |
海藻酸钠-聚乙二醇-大环配体 ;alginate-PEG-DOTAM |
115 |
wyh |
2024-11-21 |
86748 |
C6 D-threo Ceramide (d18:1/6:0),cas:189894-79-9,鞘氨醇衍生物 |
179 |
zcy |
2024-11-21 |
86749 |
DOTA-(COOt-Bu)3-azide,1402795-92-9 |
91 |
wyh |
2024-11-21 |
86750 |
cas:1957235-98-1;Thalidomide-NH-C6-NH2 hydrochloride;沙利度胺衍生物 |
102 |
zcy |
2024-11-21 |
86751 |
DOTA-cyclo(Arg-Gly-Asp-DPhe-Lys) |
120 |
wyh |
2024-11-21 |
86752 |
DOTA-TMTP1的结构与组成 |
141 |
wyh |
2024-11-21 |
86753 |
DOTA-MeTz,1610950-41-8,DOTA-甲基四嗪 |
99 |
zyl |
2024-11-21 |
86754 |
DOTA-c(RGDfK)的结构特点 |
111 |
wyh |
2024-11-21 |
86755 |
C6 NBD Ceramide,N-[6-[(7-硝基-2-1,3-苯并恶二唑-4-基)氨基]己酰基] -D-赤型-鞘氨醇 |
246 |
zcy |
2024-11-21 |
86756 |
DOTA-「Tyr3」-Octreotide ;204318-14-9 |
106 |
wyh |
2024-11-21 |
86757 |
cas:619300-53-7 DOTA NOC acetate |
105 |
zyl |
2024-11-21 |
86758 |
p-SCN-Bn-DOTA ;127985-74-4 |
96 |
wyh |
2024-11-21 |
86759 |
cas:2093386-51-5,Thalidomide-NH-C6-NH2 TFA,烷基链化合物或碳链化合物 |
190 |
zcy |
2024-11-21 |
86760 |
913528-04-8 ;DOTAM-mono-acid-CSDN |
109 |
wyh |
2024-11-21 |